Heat Shock Protein 70s as Potential Molecular Targets for Colon Cancer Therapeutics

Jennifer D Black, Khosrow Rezvani1

  • 1Division of Basic Biomedical Sciences, Sanford School of Medicine, The University of South Dakota, 414 E. Clark Street, Lee Medical Building, Vermillion, SD 57069, USA. khosrow.rezvani@usd.edu.

Abstract

Insights

Targeting heat shock protein 70 (HSP70) family members, particularly mortalin-2, shows promise for colorectal cancer (CRC) treatment. Inhibiting mortalin-2 may enhance chemotherapy effectiveness and improve patient outcomes.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Targeted therapies offer improved chemotherapy response with fewer side effects.
  • Heat shock protein 70 (HSP70) family members are explored as therapeutic targets in colorectal cancer (CRC).

Purpose of the Study:

  • To review current and future molecular therapies for CRC.
  • To assess the potential of HSP70 family members in advancing CRC drug design and discovery.

Main Methods:

  • Literature review focusing on significant and translational contributions.
  • Analysis of current clinical and investigational CRC targeted agents.
  • Examination of HSP70 family's tumorigenic functions, specifically mortalin-2.

Main Results:

  • Current targeted agents and novel investigational therapies for CRC are discussed.
  • Mortalin-2, crucial for mitochondrial biogenesis, acts as an oncoprotein in colon cancer.
  • Mortalin-2 inhibition is identified as a potential strategy to enhance patient response to chemotherapy.

Conclusions:

  • Further research into HSP70 family's role in CRC is needed.
  • Translating molecular insights into targeted therapies can improve clinical outcomes.
  • Targeting HSP70 family members may offer therapeutic synergy with cytotoxic agents.

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
65
Molecular Chaperones and Protein Folding03:00

Molecular Chaperones and Protein Folding

The native conformation of a protein is formed by interactions between the side chains of its constituent amino acids. When the amino acids cannot form these interactions, the protein cannot fold by itself and needs chaperones. Notably, chaperones do not relay any additional information required for the folding of polypeptides; the native conformation of a protein is determined solely by its amino acid sequence. Chaperones catalyze protein folding without being a part of the folded protein.
The...
20.7K